



Ref: SEC/SE/2025-26
Date: January 30, 2026

To,
Corporate Relations Department
BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai- 400001

Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, 5th Floor
Plot No. C/1, G Block Bandra – Kurla Complex
Bandra (E), Mumbai – 400051

BSE Scrip Code: 500096

NSE Scrip Symbol: DABUR

Sub: Newspaper Publication of Unaudited Financial Results for the quarter and nine months ended December 31, 2025

Dear Sir/ Madam,

Pursuant to the provisions of Regulation 30, 47 and 52 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, we are pleased to enclose copies of the newspaper publication in all editions of Mint (English newspaper), all editions of The Aaj (Hindi newspaper) and Shah Times (Hindi newspaper) dated January 30, 2026 which *inter-alia* contain Quick Response Code and the details of the webpage where complete financial results of the Company for the quarter and nine months ended December 31, 2025 are accessible to the Investors.

The afore-mentioned results were approved by the Board of Directors of the Company in its meeting held on January 29, 2026.

This is for your information and records.

Thanking you,
Yours faithfully
For **Dabur India Limited**


(Ashok Kumar Jain)
Group Company Secretary and Chief Compliance Officer

Encl: as above



InvAscent ups pharma bets with larger deals

The PE firm is participating in \$80-100 mn deals, up from \$30-50 mn

By Anshu K
privatization@livemint.com
MUMBAI

Private equity firm InvAscent is writing significantly larger cheques in pharma—its core focus—as rising regulatory and manufacturing costs have pushed companies to raise more capital. “Our ticket sizes in pharma have increased. We now participate in \$80-100 million deals along with our LPs limited partners, where we roughly do a 50:50 split. Earlier, we engaged only in \$30-50 million transactions,” founder and chairman Hari Buggana told Mint.

“It crosses a lot more ticks to build a new facility to comply with the regulations, so companies naturally need to raise a lot more money,” he added. The firm is also widening its investment lens to sub-segments such as health-tech.

This comes on the back of rising investor interest in the pharma and healthcare sectors, driven by higher income, spending, expanding healthcare coverage and growing medical tourism, creating new pockets of demand for innovation and growth from tier II and III cities.

The Hyderabad-based private equity firm is focused on three major industries—pharmaceuticals, health-tech and animal health that together constitute about 50% of the fund, followed by healthcare (about 30%) and other related industries such as med-tech, health-tech and animal health that together constitute about 20% of the fund.

The commentary follows less than a year after the investment firm closed its fourth fund with a corpus of \$104 million. By the time Fund IV is fully invested, it will likely close at \$100 million with co-investments from limited partners, he said, adding that the firm has already deployed 40% of the capital from the current fund. Its investments from the fourth fund



Rising compliance costs are pushing pharma companies to raise more capital. Mint

include Apex Hospitals, ARI Health, Fleming Laboratories, Gerti Care, SRV Hospital and Maha Pharma. The fourth fund saw a third of the capital commitments come from domestic investors, marking a first for the investment firm. The remaining capital came from international LPs. “Historically, we have always had LPs

grew. InvAscent’s fund sizes also increased—from \$100 million (2007) to \$100 million (2014), and around \$300 million in 2018, including co-investments. InvAscent is seeing public markets as a prominent exit route for its portfolio companies achieve sustainable scale. “In the past, we had several exits via sale to larger private equity firms or strategic and in some cases, the promoters decided to buy back the fund’s stake,” he said.

BIGGER CHEQUES

PHARMA remains InvAscent’s largest bet, accounting for about 50% of its fund portfolio

HEALTHCARE forms 30% of the fund, animal health, med-tech & health-tech each account for 20%

FUND IV closed at \$104 million, targets \$100 million; it has already deployed 40% of its capital from the current fund

its exits include Olyvia Skin & Hair Clinic and Oasis Fertility to Kedara Capital, and the sale of its stake in Comprehensive Prosthetics and Orthotics to Northbrook Parkway Partners. The investment firm assists promoters in three areas—capital allocation, getting the organization to a bigger scale and profitability, and employee safety and governance.

For an extended version of this story, go to livemint.com.



Powering Tomorrow's Energy

REVENUE GROWTH 61.0%
EBITDA GROWTH 62.0%
PAT GROWTH 67.7%

WEBSOL ENERGY SYSTEM LIMITED

Head Office: 5th Floor, Indraprastha Sankh, Sector 16, Gurgaon, Haryana - 122002
CIN: L29200HR1999PLC0048110
Statement of Unaudited Consolidated Financial Results for the Quarter and Nine Months ended 31st December 2025

	2025	2024	2023	2022	2021	2020
1	Total Income from operations	261.02	168.22	147.31	647.88	403.47
2	Net Profit for the period (before Tax and Extraordinary Items)	85.11	59.25	48.12	239.94	134.47
3	Net Profit for the period (after Tax and Extraordinary Items)	84.00	58.66	48.12	234.83	134.47
4	Net Profit for the period (after Tax and Extraordinary Items)	64.88	45.22	41.58	178.00	106.47
5	Total Comprehensive Income for the period (Comprising Profit and Other Comprehensive Income for the period)	65.23	45.24	41.50	178.58	106.27
6	Per Share Profit (after Tax and Extraordinary Items)	42.21	42.21	42.21	42.21	42.21
7	Other Equity	-	-	-	-	235.84
8	Earnings per Share (Basic and Diluted) (Rs. 1/- per share basis, rounded off to two decimal places)	1.54	1.10	0.99	4.23	2.52
9	Dividend Paid	1.52	1.08	0.97	4.18	2.48
10	Dividend Yield (%)	1.52	1.08	0.97	4.18	2.48

www.websolenergy.com | info@websolenergy.com | 033-4009 2100 | +91 98369 65866

DABUR INDIA LIMITED

Regd. Office: 6/3, Asaf Ali Road, New Delhi - 110 002
CIN: L24230DL1997PLC007906
Tel: New Delhi: 23252494, Fax: New Delhi: 23222081
Website: www.dabur.com | E-mail: corporate@dabur.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2025

The consolidated and standalone unaudited financial results of the Company for the quarter and nine months ended December 31, 2025, approved by the Board of Directors in their meeting held on January 29, 2026, along with the Auditors' Limited Review Reports thereon (expressing an unmodified opinion), as filed with the Stock Exchanges under Regulations 33 and 52 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 are available on the Company's website (www.bseindia.com & www.nseindia.com), the Company's webpage (www.dabur.com/investor/financial-information/results) and can also be accessed by scanning the following Quick Response Code.

For and on behalf of the Board of Directors
Place: New Delhi
Date: January 29, 2026
Mohit Burman
Chairman
DIN: 00021963

Partnering the Journey to Viksit Bharat with Innovative Financing!



Extract of Unaudited Financial Results (Standalone & Consolidated) for the Three Months and Nine Months ended 31.12.2025

Sl. No.	Particulars	Standalone						Consolidated					
		Three Months Ended			Nine Months Ended			Three Months Ended			Nine Months Ended		
		31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Audited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2023 (Audited)
1.	Total Income from Operations	14,810.88	15,084.13	14,157.19	44,641.43	40,751.88	50,811.12	15,027.70	14,271.82	14,907.82	44,907.82	41,033.01	58,368.55
	Net Profit for the period (before Tax, Extraordinary and Other Comprehensive Income)	5,116.40	5,552.80	5,109.57	15,116.10	14,475.11	19,859.78	5,154.71	5,548.94	5,109.97	16,370.06	14,627.58	20,117.47
	Net Profit for the period (after Tax and Extraordinary and Other Comprehensive Income)	5,116.40	5,552.80	5,109.57	15,116.10	14,475.11	19,859.78	5,154.71	5,548.94	5,109.97	16,370.06	14,627.58	20,117.47
	Net Profit for the period after Tax (after Extraordinary and Other Comprehensive Income)	4,043.06	4,425.86	4,029.00	12,919.95	11,477.01	15,713.21	4,052.44	4,414.83	4,076.36	12,833.08	11,574.25	15,884.23
	Total Comprehensive Income for the period (Comprising Profit and Other Comprehensive Income)	4,718.20	5,084.38	4,721.76	11,800.44	11,010.35	14,186.41	4,728.56	5,063.45	4,778.02	11,813.36	11,107.59	14,367.43
	Per Share Profit (after Tax and Extraordinary and Other Comprehensive Income)	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22	2,833.22
	Other Equity	83,629.29	80,815.08	73,888.45	63,629.29	73,888.45	75,004.75	84,380.47	80,947.53	74,822.78	84,380.47	74,532.76	75,744.84
	Securities Premium Account	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53	1,077.53
	Net Worth	86,262.48	82,735.50	75,015.07	85,262.48	75,015.07	76,082.28	86,262.48	82,735.50	75,900.31	86,262.48	82,735.50	75,900.31
	Per Share Debt Capital Outstanding Debt	4,98,826.28	5,07,496.74	4,89,585.07	4,98,826.28	4,89,585.07	4,98,826.28	4,98,826.28	4,98,826.28	4,98,826.28	4,98,826.28	4,98,826.28	4,98,826.28
	Debt Equity Ratio *	5.78	6.07	6.38	5.78	6.38	6.28						
	Earnings per Share (of ₹10 each) for continuing and discontinued operations (in ₹)	15.35	16.91	15.30	45.07	43.59	55.55	15.35	16.77	15.48	49.12	43.95	60.20
	Divided	15.35	16.91	15.30	45.07	43.59	55.55	15.35	16.77	15.48	49.12	43.95	60.20

*Net Equity Ratio = Net Debt / Net Worth (Net Debt represents principal outstanding less cash and cash equivalents available)

Notes:
1. The above financial results of the Company were reviewed by the Audit Committee and approved and taken on record by the Board of Directors at their respective meeting held on January 29, 2026. These results have been limited reviewed by the Joint Statutory Auditors of the Company.
2. The above is an extract of the consolidated financial results filed with the Stock Exchanges under Regulation 33 & 52 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015. The full text of the financial results is available on the Stock Exchange websites (www.bseindia.com & www.nseindia.com) and also on the Company's website (www.recindia.com).
3. For other applicable disclosures as required under regulation 53A) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, refer consolidated format of the financial results filed with the Stock Exchange (www.bseindia.com and www.nseindia.com) and can also be accessed on the Company's website (www.recindia.com).

Place: Delhi
Date: January 29, 2026
RECORDED DATE
The Board of Directors at its meeting held on January 29, 2026, declared 3rd interim dividend @ 45% (i.e. Rs. 45/- per equity share of face value of Rs. 100/- each) for the financial year 2025-26 and last Friday, February 6, 2026 as the "Record Date" for receiving eligible shareholders for the purpose of payment of said interim dividend.
The above dividend would be paid to all the eligible shareholders within 30 days from the date of declaration.
For REC Limited
(Chartered Secretary)
Chairman & Managing Director
DIN - 06617798

GUJARAT ENERGY TRANSMISSION CORPORATION LIMITED

Registered & Corporate Office: Sardar Patel Vihar Bhawan, Racecourse, VADODRA - 390 007
www.getco.gujarat.com & www.mprocur.com

TENDER NOTICE NO. ACE (P&C) / Tender No-22/ 2025-2026

[A] PROCUREMENT: E-3087- Purchase of MS Rail 60 Kgr/ Mtrs. - 13 Mts. as per latest specifications & Schedule-A, on firm price for year 2026-27 against Tender No. ACE (P&C) SE (P&C) / EE (P) / IV E-3087/ MS Rail/ 2026-27/ Project & RM phase-I&II.

[B] CIVIL: ACE (P&C)/CONTRACTS/CIVIL - 588 - A, 590, 591: (1) Extension of CR Building (2 Spn), Renovation & Painting of Old CR Bldg., RCC Chaff etc. Misc. civil works and Electrification Work of CR Extn. at 66 KV LILESARA SS under Godhra Division under Jamnava Circle, (2) Construction of various foundations for 220/132 KV TR Bay, RCC road, Control room extension, office building and misc. civil work at 220 KV Gondal SS Under Gondal AM Division under Gondal AM Circle, (3) Construction of Control Room Building, Foundations, Cable Trench, Compound Wall, Staff Quarter, RCC Road & misc. civil works at 66 KV Navagam S/S, Ta. - Kevadiya & District Narmada under Bharuch Circle.

[C] LINE: ACE (P&C)/CONTRACTS/ E-415/ TLV 86 KV/ S&E: Replacement of Dog conductor, earth wire and its hardware of 66 KV DIC Chhaya - Odadara Line No. 1 & 2 (Wind Farm of M/s Suzlon) hotline condition under deposit scheme (Option-1) under Jamnagar TR Circle under EPC.
[D] SUBSTATION: ACE (P&C)/CONTRACTS/ E-394, 412: (1) Supply, Erection, Testing, and Commissioning of 220 KV & 86 KV Equipment and Materials on Turnkey Basis, including Civil Works, for 220 KV Rangpur AIS Substation, (2) Supply, Erection, Testing, and commissioning of 220 KV & 86 KV Equipment's & materials on Turnkey basis including civil works for 220 KV Mahudha AIS Substation.

Above Tenders are available on website www.getco.gujarat.com (for viewing and download only) and tender.mprocur.com (for view, download and online tender submissions).
Note: Bidders are requested to be in touch with our website till opening of these tenders.

Date: 30/01/2026 I/c Additional Chief Engineer (Procurement & Contracts)

